Biogen Idec, Regulus Cut Deal to Monitor Multiple Sclerosis

Regulus Therapeutics has staked out a strategy as a developer of drugs that alter microRNA, but today it has struck a new deal with Biogen Idec to look at microRNA in a different way. The plan is to track the progress of multiple sclerosis and how patients might be responding to a given therapy.
Xconomy